AMILORIDE CLINICAL TRIAL IN OPTIC NEURITIS: TRIAL PARADIGM. Issue 10 (9th September 2014)

• Record Type: Journal Article
• Authors: McKee, Justin; Elston, John; Evangelou, Nikos; Fugger, Lars; Kennard, Christopher; Palace, Jacqueline; Craner, Matt
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 85:Issue 10(2014)
• Page Start: e4
• Page End: e4
• Publication Date: 2014-09-09
• Subjects: EPILEPSY; Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2014-309236.129
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Aims: To outine the use of Optic Neuritis as a model for neuroprotective trials To present baseline clinical data on the first 14 participants within the ACTION trial. Methods: ACTION is a phase II randomised controlled trial of amiloride vs placebo in patients with acute optic neuritis, recruited within 28 days of onset. The primary outcome measure is comparison of 6 month retinal nerve fibre layer thickness between the affected and unaffected eye. Participants undergo OCT and GDx, high and low contrast visual acuity, colour vision, Humphrey visual fields, PERG, VEP, and MRI brain. Results: 14 patients have been recruited from 47 referrals. Mean time from onset of symptoms to commencing the study drug is 14.7 days, median 13. Mean visual acuity in the affected eye is 50 letters (6/60), median 64 (6/30). 7 patients had T2 white matter lesions on baseline MRI imaging. One patient had a pre-existing diagnosis of multiple sclerosis. Conclusions: Recruiting to clinical trials in acute optic neuritis is challenging but feasible. Ongoing and future neuroprotective trials in optic neuritis require a robust and motivated network of clinicians and researchers recognising the "window of opportunity" to facilitate timely referral.